Document is current
Any future updates will be listed below
-
Authors
Beh, Chaw Yee
Yeo, Celestia Pei Xuan
Hong, Boon Hao https://orcid.org/0000-0002-2822-7480
Tan, Evelyn Mui Cheng
Tan, Kah Min
Poon, Dennis Jun Jie
Chu, Pek Lim
Susanti, Dewi
Tai, Pei Ling
Ryu, Monica
Proudfoot, James
Yeo, Eugenia Li Ling
Soo, Khee Chee
Chua, Melvin L. K. https://orcid.org/0000-0002-1648-1473
-
Funding
Funding for this research was provided by:
National Research Foundation Singapore
- License Information
-
More Information
Article History
Received: 23 July 2024
Revised: 1 December 2024
Accepted: 17 December 2024
First Online: 24 December 2024
Competing interests
: MLKC reports personal fees from Astellas, Pfizer, MSD, AstraZeneca, Varian, Janssen, IQVIA, Telix Pharmaceuticals; non-financial support from AstraZeneca; non-financial support from Veracyte Inc; grants from Ferring; personal fees and grants from Bayer; personal fees and grants from BeiGene; and consults for immunoSCAPE Inc. MLKC and KCS are co-inventors of the patent of a High Sensitivity Lateral Flow Immunoassay For Detection of Analyte in Sample (10202107837 T), Singapore, and serve on the Board of Directors of Digital Life Line Pte Ltd that owns the licensing agreement of the patent, outside the submitted work. Monica Ryu and James Proudfoot are employees of Veracyte, Inc. All other authors do not declare any conflicts of interest.
: All procedures performed in studies involving human subjects were in accordance with the ethical standard of the SingHealth Centralised Institutional Review Board (CIRB). Written informed consent was obtained from all human subjects (CIRB protocol no.: 2019/2177).
